Dec 05, 2019 8:30am EST Veru to Report Fiscal 2019 Fourth-Quarter, Full-Year Financial Results, Host Conference Call on December 12th
Oct 02, 2019 6:30am EDT Veru Announces Full Enrollment of Phase 2 Trial in Men with Prostate Cancer Treatment Induced Hot Flashes
Aug 28, 2019 8:30am EDT Veru to Participate at Three Upcoming Healthcare Investor Conferences in New York
Aug 27, 2019 8:30am EDT Veru to Ring NASDAQ Closing Bell on September 4th to Kick Off National Prostate Cancer Awareness Month
Aug 08, 2019 6:30am EDT Veru Reports Higher Net Revenues and Gross Profit for its Fiscal 2019 Third Quarter
Aug 01, 2019 8:30am EDT Veru to Report Fiscal 2019 Third-Quarter Financial Results; Host Conference Call on August 8th
Jul 18, 2019 2:07pm EDT Veru Announces Dismissal of Lawsuit; Prevails on All Counts in Motion for Summary Judgment
Jun 26, 2019 8:30am EDT Veru Announces Successful Completion of Pre-NDA Meeting with FDA for TADFIN (Tadalafil 5mg and Finasteride 5mg) Combination for the Treatment of Benign Prostatic Hyperplasia
Jun 04, 2019 8:00am EDT Veru Adds Breakthrough Novel Androgen Deprivation Therapy Formulation to its Advancing Prostate Cancer Drug Pipeline Following Successful Meeting with FDA
May 28, 2019 8:30am EDT Veru to Present at the Jefferies 2019 Global Healthcare Conference on June 4th
